Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buxu Jiedu Huayu granule (also referred to as Buxu Jiedu Huayu Decoction or Buqi Jiedu Huayu granule) is a Traditional Chinese Medicine (TCM) formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine. It is primarily investigated for the treatment of primary thrombocytosis (essential thrombocythemia). The formulation is designed to tonify deficiency, detoxify, and resolve blood stasis, which are key therapeutic principles in TCM for managing myeloproliferative disorders. Clinical evaluation focuses on its ability to reduce platelet counts and aggregation, as well as its impact on Bcl-2 levels, often when used as an adjunct to standard hydroxyurea therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Buxu Jiedu Huayu granule.